Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biohaven Pharmaceuticals
Biotech
Biohaven trashes troriluzole in OCD after ph. 3 fail
This is the second OCD trial the asset has failed and the latest in a string of clinical turbulence for the drug.
Darren Incorvaia
Aug 12, 2025 2:06pm
FDA delays decision on Biohaven troriluzole filing, plans adcomm
May 15, 2025 6:02am
Biohaven lands funding Oberland funding deal worth up to $600M
Apr 28, 2025 4:43pm
Biohaven's biopolar med fails pivotal test
Mar 3, 2025 5:14pm
Biohaven fails phase 3 SMA test but plans talks with FDA
Nov 25, 2024 9:56am
Biohaven bounces back with phase 3 ultra-rare disease win
Sep 23, 2024 9:22am
